The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new ...

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug development supply chain, covering scientific publications, clinical trials, drug ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor ...

Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.R&D Expenses was approximately RMB1319.68 ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...